IP Library Granted Patent US 9,464,292
Granted Patent B2
US 9,464,292 · App. 14/568,459 · Granted Oct 11, 2016

Sense oligonucleotide capable of controlling the expression of INOS and composition comprising the same

Inventors: Tadayoshi Okumura (Osaka, JP); Mikio Nishizawa (Osaka, JP); Yasuo Kamiyama (Osaka, JP); Koji Wakame (Sapporo, JP); Takehito Miura (Sapporo, JP)
Assignees: AMINO UP CHEMICAL CO., LTD; KANSAI MEDICAL UNIVERSITY
C12N15/1137C12N15/113C12N2310/11C12N2310/315C12N2310/3231C12N2310/3233
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,464,292
App. No.
14/568,459
Granted
Oct 11, 2016
Kind
B2
Abstract

The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.

Claims (8)

1. A sense oligonucleotide, wherein said sense oligonucleotide is a single-stranded DNA oligonucleotide which comprises a sequence complementary to human iNOS (inducible nitric oxide synthase) mRNA antisense transcript, wherein said sequence complementary to human iNOS mRNA antisense transcript is complementary to at least 16 contiguous nucleotides of SEQ ID NO: 11,

and wherein said sense oligonucleotide contains one or more non-naturally occurring modifications which stabilize the oligonucleotide against decomposition by a nucleolytic enzyme.

2. The sense oligonucleotide according to claim 1 , wherein said sequence complementary to human iNOS mRNA antisense transcript is complementary to a thermodynamically unstable loop structure in said human iNOS mRNA antisense transcript.

3. The sense oligonucleotide according to claim 1 , wherein said oligonucleotide is 16-335 bases in length.

4. The sense oligonucleotide according to claim 1 , wherein the stabilization is performed by at least one modification selected from the group consisting of phosphorothioate, LNA, PNA, ENA, and morpholino.

5. A composition comprising the sense oligonucleotide according to claim 1 , wherein said composition has an activity of suppressing production of NO by promoting decomposition of iNOS mRNA.

6. A method of controlling production of the amount of iNOS, comprising introducing the sense oligonucleotide according to claim 1 into a cell.

7. The sense oligonucleotide according to claim 1 , wherein said sense oligonucleotide consists of a nucleotide sequence complementary to a non-stem region in a stem-loop structure of human iNOS (inducible nitric oxide synthase) mRNA antisense transcript.

Assignments (1)
CHANGE OF NAME Recorded Feb 28, 2019
From: AMINO UP CHEMICAL CO., LTD.
To: AMINO UP CO., LTD.
Reel/Frame 050095/0402 →
Priority Claims (1)
JP 2006-159730 · Jun 8, 2006 · national
Continuity (2)
Continuation 12303914
Related Publication 20150191733A1 · Jul 9, 2015